The Innovative Health Initiative (IHI) is a public-private partnership (PPP) between the European Union and the European life science industries, and these partners sit on our Governing Board. Our other governance bodies ensure IHI benefits from the input of the wider scientific and health community as well as the Member States and countries associated to Horizon Europe.
The partners of IHI are the European Union, represented by the European Commission, and the European life science industry, represented by the industry associations COCIR, EFPIA (including Vaccines Europe), EuropaBio and MedTech Europe.
The Governing Board is the main decision-making body of IHI, and is made up of four representatives of the EU and four representatives of the industry partners.
The Science and Innovation Panel (SIP) provides the Governing Board with science-based advice on a range of matters. Panellists include representatives of the European Commission, IHI industry partners and the SRG as well as the scientific community and the wider healthcare community.
The States Representatives Group (SRG) consists of representatives of the EU Member States and countries associated to Horizon Europe. The group is consulted on a range of issues, including draft call topics. It also acts as a vital link between IHI and relevant national and regional research and innovation programmes.
The Executive Director is responsible for the day-to-day running of IHI and manages the Programme Office. In addition to running IHI, the Executive Director and the Programme Office continue to monitor projects launched under the Innovative Medicines Initiative (IMI), the fore-runner to IHI.
The IHI Patient Pool is a group of patients and informal caregivers who contribute their unique expertise and experience to IHI's work in diverse ways.